Nicolaus Kröger  
EBMT President

Forward

I am honored and delighted to introduce the second digital EBMT Annual Report covering EBMT’s pursuits throughout this past year. At the beginning of 2021, vaccination against SARS-CoV-2 picked up speed and we were optimistic that many of the barriers to the effective delivery of high quality transplant services across Europe would be resolved, but a third and a fourth COVID-19 wave forced us to perform nearly all of EBMT’s activities in 2021 in a virtual format. Events such as the 3rd European CAR T-cell Meeting in February as well as the 47th EBMT Annual Meeting in March were held virtually whereas other meetings such as the Joint ASTCT-EBMT Scientific Retreat was postponed until May 2022. Despite this virtual format, the European CAR T-cell Meeting and the EBMT Annual Meeting were well attended and a major success.

Also in 2021, the society made progress in both our vision and mission through science, education and advocacy.

We have been able to demonstrate a strong commitment to our patients and members by providing guidelines for transplant units, recipients and donors of hematopoietic cells. Since its start in 2020, the [EBMT COVID-19 recommendations and guidelines](#) have been regularly updated. In 2021, we were able to provide new information and the best prevention and treatment strategies for our patients and donors and the scientific community by producing these guidelines and by hosting a virtual [EBMT Summit](#) dedicated exclusively to SARS-CoV-2 and COVID-19.
The organisation learned and rapidly managed to adapt to a virtual format for its meetings, conferences and educational events, such as the **6th International Transplant Course**. All Working Parties have also increased their activity over this year and many have presented excellent educational events and/or online courses available in the [EBMT E-learning](#) platform – more detailed information is provided in the “Education” section.

We continued to intensify our collaborative relationship with our sister societies with respect to data collection harmonisation and scientific exchange. The activity of the joint EBMT-EHA [GoCART Coalition](#) has been increased and the GoCART live Clinical Case Discussions have been well attended.

Increasing regulatory requirements and proper implementation of the General Data Protection Regulation (GDPR) has led to some delay in starting the [CAR T-cell PAS studies](#) resulting in new and more efficient department structures including a Joint Controllership Agreement (JCA) between the organisation and its members.

Two new EBMT committees were founded in 2021. The [Equality, Diversity and Inclusion (EDI) Committee](#) is on a journey to address the inequalities in many aspects of patient care and broader issues. While the new EBMT [Trainee Committee](#) is focused on seeking out the specific needs of trainees working in the field of stem cell transplantation and cellular therapy and providing resources to trainees to become the next generation of leaders.

Less successful was the development of the new EBMT Registry. Due to insurmountable difficulties regarding data migration we had to stop the Registry upgrade with MACRO, but fortunately we are already working with a new provider to improve our current ProMISe data base into a user-friendly and modern registry.

While reading our 2021 Annual Report, I hope you will realise the strong and impressive resilience of the organisation, its members and its staff, despite the challenges we all faced last year and continue to face today.
2021 was again a year of remarkable progress in our society. I’d like to express my deepest gratitude to all who contributed to the activities and achievements of EBMT in 2021 including our centre members around the world who continuously report data on patient outcomes to our Registry. Such efforts have helped the EBMT Working Parties perform valid studies to refine clinical practices and improve the outcomes of patients.

Please take time to read and enjoy the 2021 Annual Report, which will be my last EBMT Annual Report since, in March 2022, I will be stepping down as EBMT President to recognise a new chapter of the society under the leadership of Anna Sureda.

Thank you for your tenacious commitment to EBMT and our community.

Yours truly,

Nicolaus Kröger

*EBMT President*

Read more Read less

EBMT

2021

**Science**
As Scientific Council Chair I have the privilege to summarize our achievements in 2021. I was ready to draw you a picture of relief and uplift for 2022. I guess I have to rephrase my words cautiously with regard to what we can expect for at least the first quarter of 2022.

It looks like the COVID-19 pandemic turns into a Netflix series, with ever new twists and turns and new actors dominating the new season. On the other hand, I feel that we are all getting more and more experienced and relaxed, ready to handle the situation...

Working Parties Activity Reports

Severe Aplastic Anaemia Working Party (SAAWP)
Autoimmune Diseases Working Party (ADWP)
Acute Leukaemia Working Party (ALWP)
Cellular Therapy and Immunobiology Working Party (CTIWP)
Infectious Diseases Working Party (IDWP)
Inborn Errors Working Party (IEWP)
Lymphoma Working Party (LWP)
Paediatric Diseases Working Party (PDWP)
Chronic Malignancies Working Party (CMWP)
Transplant Complications Working Party (TCWP)

More in science

EBMT Publications 2021
EBMT Transplant Activity Survey 2020
EBMT Registry

Committees Activity Reports

Statistical Committee
Global Committee
Pharmacists Committee
EBMT
2021

Education
In many ways, 2021 felt like an encore of 2020, as COVID-19 continued to dominate every part of our lives. The hope that the vaccine rollout brought us was overshadowed by news of the delta variant in the summer, and omicron in November.

For the EBMT’s Education and Events Department, 2021 started with virtual editions of our two largest events. In February, we organized the third edition of the European CAR T-Cell Meeting, a joint project with the European Hematology Association. This meeting has quickly become one of the most important events in the field of CAR T-cell therapies, and draws an international audience...

**Educational activities**
Committees Activity Reports

Trainee Committee

Improving the care of our patients is a critical objective of the EBMT. We believe in
empowering, advocating and amplifying the interests of patients, survivors, and caregivers worldwide. Be sure to check out the many achievements from the Nurses Group, JACIE, the EBMT Legal & Regulatory Affairs Committee and the EBMT Patient Advocacy Committee throughout this past year. You should also catch up on the recent activities of the GoCART Coalition - a collaborative multi-stakeholder Coalition launched in 2020 that is helping play a key role in combating complex diseases and saving lives.

Patient Care & Advocacy Initiatives

EBMT Nurses Group Activity Report 2021
Highlights of the JACIE's Activities
GoCART Coalition

Committees Activity Reports

Legal & Regulatory Affairs Committee
Patient Advocacy Committee

Financial Report & Highlights 2021

As treasurer of our society, I am proud that we have endured the financial risks faced during the global COVID-19 pandemic and its extensive worldwide impact. After the coronavirus breakout in 2020, a contingency plan was developed to secure staff positions and strategic investments. This has allowed us to invest in our strategic mission in 2021 while building some financial reserves in order to face present and future uncertainties. We were able to close 2021 with a positive financial result and EBMT continues to invest in its strategic goals in line with its mission... Read more
See the financial report

Our Society

Our Mission, Vision & Values
Equality, Diversity & Inclusion
Membership 2021
Organisational Structure 2021
Financial Report & Highlights 2021
EBMT Partners 2021

See past Annual Reports